* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
Adam Koppel
Partner of Bain Capital Life Sciences Investors, LLC
Boston, Massachusetts
11/14/2025
Bain Capital Life Sciences Investors, LLC ("BCLSI") is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general partner of Bain Capital Life Sciences Fund II, L.P., which is the manager of BCLS II Investco (GP), LLC, which is the general partner of BCLS II Investco, LP, and (iii) the manager of Bain Capital Life Sciences III General Partner, LLC, which is the general partner of Bain Capital Life Sciences Fund III, L.P., which is the (a) sole member of Bain Capital Life Sciences Opportunities III GP, LLC, which is the general partner of Bain Capital Life Sciences Opportunities III, LP and (b) the managing member of BCLS Fund III Investments GP, LLC, which is the general partner of BCLS Fund III Investments, LP. The information included on the Information Table with respect to the holdings of Annexon Inc. ("ANNX"), Cabaletta Bio, Inc. ("CABA"), Cidara Therapeutics, Inc. ("CDTX"), NewAmsterdam Pharma Company NV ("NAMS"), Olema Pharmaceuticals, Inc. ("OLMA"), Savara Inc. ("SVRA"), Solid Biosciences Inc. ("SLDB"), X4 Pharmaceuticals, Inc. ("XFOR") and Xilio Therapeutics, Inc. ("XLO") reflect the exercise or conversion of warrants or other convertible securities held by affiliates of BCLSI after giving effect to provisions that prevent the exercise of such securities if the beneficial ownership of such persons would exceed 9.99% of the underlying security following such exercise. As of September 30, 2025, affiliates of BCLSI held an aggregate of 4,474,126 shares of ANNX common stock, 4,260,888 shares of CABA common stock, 2,100,000 shares of CDTX common stock, 10,473,913 ordinary shares of NAMS, 6,696,640 shares of OLMA common stock, 14,789,777 shares of SVRA common stock, 5,034,582 shares of SLDB common stock, 495,991 shares of XFOR common stock and 2,805,413 shares of XLO common stock.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.